Analysts Set Alcobra Ltd. (NASDAQ:ADHD) Target Price at $5.17
Alcobra Ltd. (NASDAQ:ADHD) has earned an average rating of “Hold” from the ten brokerages that are presently covering the company. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $5.17.
A number of brokerages recently weighed in on ADHD. Roth Capital set a $8.00 price objective on shares of Alcobra and gave the company a “buy” rating in a research report on Saturday, October 1st. Piper Jaffray Cos. downgraded shares of Alcobra from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $10.00 to $3.00 in a research report on Thursday, September 29th. Cantor Fitzgerald downgraded shares of Alcobra from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a research report on Thursday, September 29th. Zacks Investment Research upgraded shares of Alcobra from a “sell” rating to a “hold” rating in a research report on Tuesday, July 26th. Finally, Jefferies Group restated a “buy” rating and set a $6.00 price objective (down previously from $9.00) on shares of Alcobra in a research report on Monday.
Shares of Alcobra (NASDAQ:ADHD) opened at 2.71 on Monday. The stock’s market cap is $74.69 million. Alcobra has a 52 week low of $1.95 and a 52 week high of $8.78. The stock’s 50 day moving average is $4.48 and its 200 day moving average is $4.47.
Alcobra (NASDAQ:ADHD) last issued its quarterly earnings data on Tuesday, August 30th. The company reported ($0.21) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.01. On average, equities analysts forecast that Alcobra will post ($0.94) EPS for the current year.
A number of hedge funds have recently made changes to their positions in the stock. Franklin Resources Inc. boosted its stake in shares of Alcobra by 28.2% in the first quarter. Franklin Resources Inc. now owns 3,652,931 shares of the company’s stock worth $13,845,000 after buying an additional 804,350 shares in the last quarter. BlackRock Fund Advisors boosted its stake in shares of Alcobra by 11.4% in the first quarter. BlackRock Fund Advisors now owns 354,614 shares of the company’s stock worth $1,344,000 after buying an additional 36,218 shares during the period. Jefferies Group LLC purchased a new stake in shares of Alcobra during the second quarter worth about $533,000. VHCP Management II LLC boosted its stake in shares of Alcobra by 28.7% in the second quarter. VHCP Management II LLC now owns 1,454,402 shares of the company’s stock worth $6,530,000 after buying an additional 323,902 shares during the period. Finally, VHCP Management LLC boosted its stake in shares of Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock worth $2,799,000 after buying an additional 138,813 shares during the period. 73.69% of the stock is owned by institutional investors and hedge funds.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Stock Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related stocks with our FREE daily email newsletter.